DESFECHOS DO TRATAMENTO DE HEPATITE VIRAL C NO AMBULATÓRIO CENTRAL DA UNIVERSIDADE DE CAXIAS DO SUL
Keywords:
Hepatite C, Interferon-alfa, RibavirinaAbstract
Introdução: A hepatite crônica pelo vírus da Hepatite C (VHC) é um importante problema de saúde pública mundial, acometendo cerca de 3% da população mundial, e que somente 22% destas saibam de seu diagnóstico.
Métodos: Coorte histórica, analisando 28 pacientes submetidos à terapia do VHC atendidos no Ambulatório Central da Universidade de Caxias do Sul no período de 01 de Janeiro de 2007 a 31 de Dezembro de 2009.
Resultados: Obteve-se resposta viral sustentada (RVS) em 57,1% (n = 16) e 52,9% sem RVS (n = 12). O genótipo viral, o grau de fibrose hepática pelo escorre de Metavir, carga viral ao início do tratamento foram comparados e não interferiram na taxa de RVS na análise univariada.
Conclusão: A taxa de RVS assemelha-se à descrita na literatura para coortes nacionais e internacionais.
References
Sagir A, Heintges T, Akyazi Z, et al. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis virus infection. Liver Int 2007;27: 954-959.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2ª plus ribavirin for chronic hepatotis C vírus infection. N Engl J Med 2002;347:975-982.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a radomized trial. Lancet 2001; 358: 958-965.
Sangik OH, Nezam H, Afdahal, et al.Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Clin Dis N Am 2006;20:99-113.
Protocolo Clínico e Diretrizes Terapêutica para Hepatite Viral C: Secretária de Vigilância em Saúde. Ministério de Saúde do Brasil. Portaria N° 34 de Setembro de 2007:
Lorna M. A general approach of management of hepatitis Chronic C.Gastroenterol Clin N Am;2004; 33: 463-477.
Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity is a key factor in the determining the natural history of chronic hepatitis C. Hum Pathol.2001:32; 904-909.
Nancy WY, Lum PJ, et al. Management of viral hepatitis C. Journal of Gastroenterology and hepatology;2002; 17:146-154.
Kim WR. The burden of hepatitis C in U.S. Hepatology.2002;36(5 suppl 1).30-34.
Davis GL, Monitoring of viral levels during therapy of hepatitis C. Hepatology, 2002; 36: 145-151.
Manns MP, McHuchington JG, Gordon SC, et al. Peginterferon-alfa2a plus ribavirin compared with Peginterferon-alfa 2b plus ribavirin in initial treatment of chronic hepatitis C; a randomizated study. Lancet.2001:358;958-965.
Fried MW, Shiffman ML, Reddy M et al. Peginterferon-alfa 2a plus ribavirin in the treatment of chronic hepatitis C infection. New England J M.2002: 47, 352-357.
Kostman KR, et al. Management of Chronic Hepatitis C. BMJjournals.2010;299-302.
Poynard T, Colombo C, Bruix J, Schiff E, et al. Peginterferon alfa-2b and Ribavirin: Efective in patients with Hepatitis C who failed Interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-1628.
Jacobson IM, Brown RS, Freilich B, et al. Peguinterferon alfa -2b and weight based or flat-dose ribavirin in chronich hepatitis C patients: a randomized trial. Hepatology 2009; 147: 971-981.
Consenso da Sociedade Paulista de Infectologia para manuseio e terapia da Hepatite C. Sociedade Paulista de Infectologia, Maio/2010.
Heathcote J, Main J. Treatment of Hepatitis C.Journal of Hepatitis. 2008; 12; 223-235.
Lindsay K, Trepo C, Heigtges T, et al. A randomized, double blind trial compared pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2009; 147: 982-986.
Poynard T, Yuen M-F, Ratziu V, Lay C-L. Viral Hepatitis C. Lancet 2003; 362:2095-2100.
Fargion S, Francanzani AL, Valenti L, et al. Treatment choices for people infected HCV virus. Journal of Antimicrobial Chemotherapy (2009)53;708-712.
Parise E, Crespo D, et al.Peginterferon alfa-2ª plus ribavirin in treatment of chronic hepatitis C patients. Braz J Infect Dis 2008; 10 11-16.
Ghany MG, Strader DB, Thomas DL, Seeff LB;American Association for the Study of Liver Disease. Diagnosis, management and treatment for chronic hepatitis C: an update. Epatology.2009;49(4):1335-1374.
Davis GL, Wong JB, McHutchinson JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with pegiterferon alfa 2bplus ribavirin in patiente=s with chronic hepatitis C. Hepatology.2003;38(3):645-52.
Berg T, Von Wagner M, Nasser S, Sarrazin C, Heitgens T, Gerlach T, et al Extended treatment duration for hepatitic C virus type 1; comparing 48 c=versus 72 weeks of peginterferon-alfa 2a plus ribavirin. Gastroenterology.2006;130(4):1086-97.
Kwo P, Lawitz E, Mc Cone J, et al. Broceprevir plus peginterferon alfa 2b/ribavirin for tereatment of genotype 1 chronic hepatitis C in previus untreated patients: interim results from HCV sprint-1 Study-AASLD 2008, abstract LB 16
Yu Ml, Day Cy, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomized study of peguinterferon and ribavirnfor 24 weeks in patients with genotype 2 /chronic hepatitis C. Gut.2007;56(4):553-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Arquivos Catarinenses de Medicina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
